Chronic kidney disease (CKD) affects 697.5 million people every year. Reduced glomerular filtration rate (GFR) and increased albuminuria are characteristics of CKD that are more commonly witnessed in diabetes mellitus patients, affecting one patient in every three. For several years, ACE inhibitors and angiotensin II receptor blockers (ARB), the known antihypertensives, were the mainstay of CKD treatment that provided significant renal and cardiovascular protection. Then came sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of drugs recently approved for the treatment of type 2 diabetes mellitus.
They inhibit the reabsorption of glucose in the early proximal tubule, and have shown improvement in renal function of CKD patients, making them a promising therapeutic option for such patients. To shed more light on the potential of SGLT2 inhibitors in CKD, we have Dr. Bharat V.…
